This research study is being done in participants with advanced B-cell malignancies such as some types of lymphomas or leukemias. B-cell malignancies express a protein called the Bruton's tyrosine kinase (BTK), which has been shown to help the tumor cells grow and survive. The investigational drug, AC676, has been designed to recognize the BTK protein, and marks it for destruction. By destroying the BTK protein, the malignancy may be stopped from growing. "Investigational" means the study drug being tested is not approved by the FDA. This is an open-label study, meaning all patients who are eligible to participate will receive study drug. The key purposes of this study are to: ● Test the study drug at different dose levels (dose-escalation) and to determine the highest dose that can be taken without side effects that can't be tolerated (referred to as maximum tolerated dose or MTD). ● Determine what dose of

The purpose of this research study is to compare the effectiveness of two combinations of anticancer study drugs in treating your Chronic Lymphocytic Leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. The aim is to determine which combination of study drugs is more effective in controlling your specific type of cancer,

Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL) that has transformed to aggressive lymphoma called Richter's Transformation (RT)? Then you may be able to participate in this study whose purpose is to evaluate the efficacy and safety of glofitamab as monotherapy and in combination with polatuzumab vedotin or atezolizumab for participants with Richter's Transformation (RT) that has transformed from chronic lymphocytic leukemia (CLL). These are targeted immune-based therapies standardly used to treat lymphoma and/or other cancers that may also work well for RT

Do you have a type of cancer known as Relapsed Hodgkin's Lymphoma?Has your cancer come back, or not get better with the last treatment you received ? If so, you may be able to participate in a gene therapy study to see if we can use your body's own immune cells as a treatment for your HL. (Example: Do you know your blood pressure? Do you sit too much at work? If you have a desk job and higher than normal blood pressure (but are not taking blood pressure medication), you may be able to participate in a research study to find out if sitting less during the workday can lower

Is your child between the ages of 8-21, newly diagnosed with Leukemia or Lymphoma, and plans to receive chemotherapy treatment? If so, you may be able to participate in a research study investigating the feasiblity of a dietary intervention during treatment.

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

We are seeking volunteers for a survey to learn what may encourage and discourage cancer patients to be in cancer research studies. We'd like to hear from you if you are: -18 years+ -Have been diagnosed with cancer or the caregiver of someone diagnosed with cancer. -Spend time in Bertie, Hertford, Robeson or Scotland County, NC or a neighboring county. Participation includes 1 survey (about 10 minutes long) that can be done with your mobile device, computer, or by phone with the researcher. Compensation: 1 in 10 participants will receive a $25 Visa gift card.

This study enrolling people who recurrent (has come back) or refractory (did not respond to treatment) classical Hodgkin lymphoma or CD30-positive peripheral T-cell lymphoma (PTCL). The purpose of this study is to learn about the effectiveness and safety of a new study drug called AFM13 when used in combination with a new cell therapy called AB-101. The study will also look at how the body processes this combination of drugs (called "pharmacokinetics").

We are doing this study to test a behavioral lifestyle program designed specifically for adolescent and young adult cancer survivors. Study participants will use a smartphone app and Fitbit activity tracker to help them develop healthier habits.